表紙
市場調査レポート

Biotie Therapies Corp.:製品パイプライン分析

Biotie Therapies Corp. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 214140
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Biotie Therapies Corp.:製品パイプライン分析 Biotie Therapies Corp. - Product Pipeline Review - 2015
出版日: 2015年12月30日 ページ情報: 英文 34 Pages
概要

Biotie Therapies Corp.は、パーキンソン病やアルツハイマー病、その他の認識力障害といった神経変性疾患、精神疾患、炎症性疾患、線維性疾患向けの治療薬の創薬、開発を行う製薬企業です。

当レポートでは、Biotie Therapies Corp.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Biotie Therapies Corp.の基本情報

Biotie Therapies Corp.の概要

  • 主要情報
  • 企業情報

Biotie Therapies Corp.:R&Dの概要

  • 主な治療範囲

Biotie Therapies Corp.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Biotie Therapies Corp.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Biotie Therapies Corp.:薬剤プロファイル

  • nepicastat hydrochloride
  • tozadenant
  • BTT-1023
  • SYN-114
  • SYN-120
  • 統合失調症のためのPDE-10を阻害する小分子

Biotie Therapies Corp.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Biotie Therapies Corp.:最近のパイプライン動向

Biotie Therapies Corp.:休止中のプロジェクト

Biotie Therapies Corp.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • buprenorphine hydrochloride
    • AWD-12281
    • BTT-1507
    • nitisinone
    • rufinamide

Biotie Therapies Corp.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07937CDB

Summary

Global Markets Direct's, 'Biotie Therapies Corp. - Product Pipeline Review - 2015', provides an overview of the Biotie Therapies Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biotie Therapies Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Biotie Therapies Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biotie Therapies Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Biotie Therapies Corp.'s pipeline products

Reasons to buy

  • Evaluate Biotie Therapies Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biotie Therapies Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biotie Therapies Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biotie Therapies Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biotie Therapies Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biotie Therapies Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Biotie Therapies Corp. Snapshot
    • Biotie Therapies Corp. Overview
    • Key Information
    • Key Facts
  • Biotie Therapies Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Biotie Therapies Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Biotie Therapies Corp. - Pipeline Products Glance
    • Biotie Therapies Corp. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Biotie Therapies Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Biotie Therapies Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Biotie Therapies Corp. - Drug Profiles
    • tozadenant
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BTT-1023
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SYN-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Biotie Therapies Corp. - Pipeline Analysis
    • Biotie Therapies Corp. - Pipeline Products by Target
    • Biotie Therapies Corp. - Pipeline Products by Route of Administration
    • Biotie Therapies Corp. - Pipeline Products by Molecule Type
    • Biotie Therapies Corp. - Pipeline Products by Mechanism of Action
  • Biotie Therapies Corp. - Recent Pipeline Updates
  • Biotie Therapies Corp. - Dormant Projects
  • Biotie Therapies Corp. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • buprenorphine hydrochloride
      • AWD-12281
      • nitisinone
      • rufinamide
      • vepalimomab
  • Biotie Therapies Corp. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Biotie Therapies Corp., Key Information
  • Biotie Therapies Corp., Key Facts
  • Biotie Therapies Corp. - Pipeline by Indication, 2015
  • Biotie Therapies Corp. - Pipeline by Stage of Development, 2015
  • Biotie Therapies Corp. - Monotherapy Products in Pipeline, 2015
  • Biotie Therapies Corp. - Out-Licensed Products in Pipeline, 2015
  • Biotie Therapies Corp. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Biotie Therapies Corp. - Phase III, 2015
  • Biotie Therapies Corp. - Phase II, 2015
  • Biotie Therapies Corp. - Preclinical, 2015
  • Biotie Therapies Corp. - Pipeline by Target, 2015
  • Biotie Therapies Corp. - Pipeline by Route of Administration, 2015
  • Biotie Therapies Corp. - Pipeline by Molecule Type, 2015
  • Biotie Therapies Corp. - Pipeline Products by Mechanism of Action, 2015
  • Biotie Therapies Corp. - Recent Pipeline Updates, 2015
  • Biotie Therapies Corp. - Dormant Developmental Projects,2015
  • Biotie Therapies Corp. - Discontinued Pipeline Products, 2015
  • Biotie Therapies Corp., Other Locations
  • Biotie Therapies Corp., Subsidiaries

List of Figures

  • Biotie Therapies Corp. - Pipeline by Top 10 Indication, 2015
  • Biotie Therapies Corp. - Pipeline by Stage of Development, 2015
  • Biotie Therapies Corp. - Monotherapy Products in Pipeline, 2015
  • Biotie Therapies Corp. - Pipeline by Top 10 Target, 2015
  • Biotie Therapies Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Biotie Therapies Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Biotie Therapies Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top